Celia ReyesHoke - Liquidia Technologies VP Culture
| LQDA Stock | USD 11.52 0.10 0.86% |
Insider
Celia ReyesHoke is VP Culture of Liquidia Technologies
| Address | 419 Davis Drive, Morrisville, NC, United States, 27560 |
| Phone | 919 328 4400 |
| Web | https://www.liquidia.com |
Liquidia Technologies Management Efficiency
The company has return on total asset (ROA) of (0.4069) % which means that it has lost $0.4069 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8173) %, meaning that it created substantial loss on money invested by shareholders. Liquidia Technologies' management efficiency ratios could be used to measure how well Liquidia Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.74. The current year's Return On Capital Employed is expected to grow to -0.7. At present, Liquidia Technologies' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 2.3 M, whereas Total Assets are forecasted to decline to about 80.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Philip Scalzo | Biomarin Pharmaceutical | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Molly Cogan | NRX Pharmaceuticals | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Jeff Fairman | Vaxcyte | 60 | |
| Robert MIM | NRX Pharmaceuticals | 58 | |
| Thomas MBA | Kalvista Pharmaceuticals | 49 | |
| Tanya MS | Replimune Group | 53 | |
| Brenda JD | Bio Techne Corp | 66 | |
| MSC MBA | Mirum Pharmaceuticals | 54 | |
| John Castle | Agenus Inc | N/A | |
| BCh BM | Kronos Bio | 40 | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Bahija Jallal | Immunocore Holdings | 63 | |
| Annelise Vuidepot | Immunocore Holdings | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Francis Conway | Larimar Therapeutics | N/A | |
| Stephanie Yao | Kronos Bio | N/A | |
| Dennis McBride | NRX Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.82 | ||||
| Return On Asset | -0.41 |
Liquidia Technologies Leadership Team
Elected by the shareholders, the Liquidia Technologies' board of directors comprises two types of representatives: Liquidia Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Liquidia. The board's role is to monitor Liquidia Technologies' management team and ensure that shareholders' interests are well served. Liquidia Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Liquidia Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Almond, Director Communications | ||
| Robert Lippe, Chief Operations Officer | ||
| Russell Schundler, General Secretary | ||
| Rajeev MD, Chief Officer | ||
| Ginger Denison, CoFounder | ||
| Roger Jeffs, CEO Director | ||
| Michael Hunter, Senior Operations | ||
| William Kenan, CoFounder | ||
| Jason Adair, Chief Officer | ||
| Celia ReyesHoke, VP Culture | ||
| Tushar MD, Senior Development | ||
| Sarah SPHR, Vice Culture | ||
| Scott Moomaw, Chief Officer | ||
| Michael Kaseta, Chief Officer |
Liquidia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Liquidia Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.82 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (7.43) % | ||||
| Current Valuation | 781.38 M | ||||
| Shares Outstanding | 84.64 M | ||||
| Shares Owned By Insiders | 19.48 % | ||||
| Shares Owned By Institutions | 54.31 % | ||||
| Number Of Shares Shorted | 10.26 M | ||||
| Price To Earning | (2.61) X | ||||
| Price To Book | 8.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Liquidia Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Liquidia Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Liquidia Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Liquidia Technologies Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Liquidia Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Liquidia Stock refer to our How to Trade Liquidia Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Liquidia Technologies. If investors know Liquidia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Liquidia Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.62) | Revenue Per Share 0.21 | Quarterly Revenue Growth (0.23) | Return On Assets (0.41) | Return On Equity (1.82) |
The market value of Liquidia Technologies is measured differently than its book value, which is the value of Liquidia that is recorded on the company's balance sheet. Investors also form their own opinion of Liquidia Technologies' value that differs from its market value or its book value, called intrinsic value, which is Liquidia Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Liquidia Technologies' market value can be influenced by many factors that don't directly affect Liquidia Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Liquidia Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Liquidia Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Liquidia Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.